ストックスクリーナーアプリを入手
12.37
1.90%
-0.24
アフターアワーズ：
11.98
-0.39
-3.15%
前日終値:
$12.61
開ける：
$12.37
24時間の取引高:
3.02M
Relative Volume:
0.54
時価総額：
$4.01B
収益：
$79.21M
当期純損益:
$-143.96M
株価収益率:
-25.79
EPS:
-0.4796
ネットキャッシュフロー:
$-189.60M
1週間 パフォーマンス:
-3.59%
1か月 パフォーマンス:
+10.74%
6か月 パフォーマンス:
+228.99%
1年 パフォーマンス:
+120.11%
1日の値動き範囲:
$12.26
$12.84
1週間の範囲:
$11.93
$13.05
52週間の値動き範囲:
$2.745
$15.02
Abcellera Biologics Inc Stock (ABCL) Company Profile
Compare ABCL vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
12.37 | 4.01B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
498.50 | 126.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.30 | 90.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
778.36 | 80.14B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.30 | 51.46B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.52 | 41.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-12 | 開始されました | UBS | Buy |
| 2026-09-29 | 開始されました | JP Morgan | Overweight |
| 2026-09-24 | 開始されました | Goldman | Neutral |
| 2026-07-07 | アップグレード | The Benchmark Company | Hold → Buy |
| 2026-05-05 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-11-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | 再開されました | Leerink Partners | Outperform |
| 2024-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-02-22 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 再開されました | Piper Sandler | Overweight |
| 2023-02-28 | 開始されました | Cowen | Outperform |
| 2022-12-15 | 開始されました | Goldman | Buy |
| 2022-11-16 | 開始されました | Truist | Buy |
| 2021-12-21 | 開始されました | The Benchmark Company | Buy |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-01-05 | 開始されました | Berenberg | Buy |
| 2021-01-05 | 開始されました | Credit Suisse | Outperform |
| 2021-01-05 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | Stifel | Buy |
すべてを表示
Abcellera Biologics Inc (ABCL) 最新ニュース
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates - Zacks Investment Research
Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera - GlobeNewswire Inc.
QScreen AI settles $681K debt with shares, pres... - Pluang
Abcellera Biologics stock hits 52-week high at 12.58 USD By Investing.com - Investing.com India
Abcellera Biologics stock hits 52-week high at 12.58 USD - Investing.com
AbCellera at Cantor healthcare conference: nk3r drug boosts hopes By Investing.com - Investing.com South Africa
AbCellera at Cantor healthcare conference: nk3r drug boosts hopes - Investing.com
AbCellera at Cantor healthcare conference: nk3r drug boosts hopes By Investing.com - Investing.com UK
AbCellera Biologics (ABCL) Institutional Ownership 2026 - MarketBeat
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 - investingnews.com
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 - Yahoo Finance
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $30 - Moomoo
AbCellera Biologics (ABCL) Q4 2025 Earnings: Results, Market Reaction & History - 24/7 Wall St.
AbCellera Biologics Stock (ABCL) Opinions on Recent Surge and Insider Buying - Quiver Quantitative
Historical Data for AbCellera Biologics Inc. Tokenized Stock (Robinhood) in USD - CryptoRank
What'sGoing On With AbCellera Biologics Stock On Tuesday? - Benzinga
ABCL Stock Surges As ABCL635 Data Reprices Hot-Flash Market - timothysykes.com
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
AbCellera Biologics (ABCL) Reports Phase 2 Success, Is It Still A Bargain? - simplywall.st
AbCellera (ABCL) Levels: Posts a 8.00% Gain to $12.01 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance on the DayInverse ETF Flow - dars.gov.et
Abcellera director John S. Montalbano acquires common shares worth $110,300 - Bitget
AbCellera Biologics Director John S. Montalbano Acquires 10,000 Shares on August 18, 2026 - Kalkine Media
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Director Montalbano John S. - Moomoo
BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Abcellera Biologics stock hits 52-week high at 11.51 USD - Investing.com
Abcellera Biologics stock hits 52-week high at 11.51 USD By Investing.com - Investing.com India
Abcellera Biologics stock hits 52-week high at 11.51 USD By Investing.com - Investing.com UK
Why AbCellera (ABCL) Is Up 64.2% After Menopause Trial Win, Equity Raise And Vertex Deal - simplywall.st
AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity - Yahoo Finance
AbCellera Biologics Stock (ABCL) Opinions on Positive Phase 2 Trial Results - Quiver Quantitative
Why AbCellera (ABCL) Is Up 64.2% After Menopause Trial Win, Equity Raise And Vertex Deal - webull.com
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? - Yahoo Finance
AbCellera Biologics Inc. • Robinhood Token (ABCL) Price, MarketCap, Charts and Fundamentals Info - BeInCrypto
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Booth Andrew - Moomoo
AbCellera Biologics Director Michael R. Hayden Acquires 46,387 Shares at $10.37 Average Price - Kalkine Media
AbCellera CFO Andrew Booth Acquires 37,200 Shares at $10.32 Each - Kalkine Media
AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85% - Trefis
6 Green Days In A Row: AbCellera Biologics Stock Is Up 85% - Trefis
AbCellera prices US $200M offering at US $9.75 a share - Private Capital Journal
AbCellera Biologics | 424B5: Prospectus - Moomoo
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Director Hayden Michael R - Moomoo
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
AbCellera Director Michael R. Hayden Donates 50,000 Shares to Charity via Genworks 2 Consulting - Kalkine Media
AbCellera Biologics Announces Oversubscribed $200 Million Offering - TipRanks
AbCellera Enters Underwriting Agreement for $187M Equity Offering With Jefferies, J.P. Morgan - TradingView
AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031 - Bybit
AbCellera Biologics (NASDAQ:ABCL) Sees Large Volume IncreaseTime to Buy? - MarketBeat
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - AOL.com
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Revenue Downgrade: Here's What Analysts Forecast For AbCellera Biologics Inc. (NASDAQ:ABCL) - 富途牛牛
Abcellera Biologics Inc (ABCL) 財務データ
収益
当期純利益
現金流量
EPS
2.04%
3.63%
大文字化:
|
ボリューム (24 時間):